How do you select systemic therapy for recurrent HR+ HER2 negative breast cancer in the bones in a premenopausal woman within a year of starting adjuvant AI with OFS plus abemaciclib and zoledronic acid?
She had been initially treated with neoadjuvant AC-T followed by BCS and RT with high burden residual disease in the breast and lymph nodes.
1 Answer
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on · Updated on
This is, unfortunately, a case of primary endocrine resistance, and recurrence on adjuvant Abemaciclib makes the case more challenging for this pre-menopausal patient.
It would be reasonable to repeat tissue biopsy to rule out a change in hormone receptor status and consider blood based ctDNA analysi...
Join for free or sign in to see the full answer